Recursion Appoints Fred Hassan as Chair of the Board
Key Highlights
- ➤Fred Hassan appointed Recursion board chair, effective October 31, 2026
- ➤Hassan brings more than four decades of pharmaceutical industry experience
- ➤Najat Khan says leadership will advance Recursion from clinical proof through approval and launch
Expert Statements
Najat Khan, President and Chief Executive Officer of Recursion
“Fred has repeatedly built, scaled and transformed some of the most important companies in our industry. His first-hand experience will bring invaluable perspective as we advance from clinical proof of concept through approval and launch - and ultimately to meaningful impact for patients. Our next chapter becomes even more exciting with Fred as Chair. The Board remains deeply grateful to Rob Hershberg for his steady commitment to Recursion, and we’re delighted that we will continue to benefit from his perspective as a physician-scientist and biotech CEO”
Fred Hassan, Chair of the Board of Recursion
“What excites me is the prospect of chairing a Board where its dynamic CEO pairs the courage of striking into the unknown with the unrelenting discipline of turning prioritized projects into innovative medicines”
Rob Hershberg, Director of Recursion
“Fred brings proven operating experience, a well-honed investor’s discipline and a track record of repeatedly creating important value through transformation. The Board unanimously believes that he is the right person for the Chair’s role. I welcome Fred and look forward to my continuing role on the Board”
Salt Lake City, UT, Nov. 02, 2026 (GLOBE NEWSWIRE) -- Recursion (Nasdaq: RXRX), a leading clinical-stage company pioneering AI-enabled drug discovery and development, today announced that its Board of Directors has appointed Fred Hassan as Chair, effective October 31, 2026
Mr. Hassan arrives with a strong track record of more than four decades in the pharmaceutical industry. He has grown global businesses and led teams that brought multiple medicines through development, regulatory approval and commercial launch. As an example, the severely challenged Schering-Plough returned to sales growth, strong cash flow, and expanded the number of new molecular entities in Phase 3 development from three to eight.
Get started
Create a free account to read the full story.